![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CSF3R |
Gene summary for CSF3R |
![]() |
Gene information | Species | Human | Gene symbol | CSF3R | Gene ID | 1441 |
Gene name | colony stimulating factor 3 receptor | |
Gene Alias | CD114 | |
Cytomap | 1p34.3 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q99062 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1441 | CSF3R | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 2.06e-02 | 7.10e-01 | -0.1408 |
1441 | CSF3R | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 4.11e-25 | 7.39e-01 | -0.0166 |
1441 | CSF3R | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.05e-29 | 8.21e-01 | -0.0132 |
1441 | CSF3R | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 2.45e-34 | 8.29e-01 | -0.013 |
1441 | CSF3R | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 7.27e-23 | 6.91e-01 | -0.0121 |
1441 | CSF3R | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 5.96e-04 | 6.71e-01 | -0.0961 |
1441 | CSF3R | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 1.19e-04 | 6.40e-01 | -0.0876 |
1441 | CSF3R | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 1.11e-04 | 6.88e-01 | -0.0822 |
1441 | CSF3R | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 2.24e-03 | 5.28e-01 | -0.0809 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Lung | ![]() | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00300998 | Lung | IAC | myeloid cell differentiation | 70/2061 | 381/18723 | 1.12e-05 | 3.45e-04 | 70 |
GO:00456378 | Lung | IAC | regulation of myeloid cell differentiation | 36/2061 | 210/18723 | 4.70e-03 | 3.68e-02 | 36 |
GO:19037068 | Lung | IAC | regulation of hemopoiesis | 56/2061 | 367/18723 | 7.23e-03 | 4.94e-02 | 56 |
GO:003009913 | Lung | AIS | myeloid cell differentiation | 63/1849 | 381/18723 | 3.05e-05 | 9.70e-04 | 63 |
GO:004563713 | Lung | AIS | regulation of myeloid cell differentiation | 35/1849 | 210/18723 | 1.43e-03 | 1.74e-02 | 35 |
GO:003009923 | Lung | AAH | myeloid cell differentiation | 29/613 | 381/18723 | 2.44e-05 | 3.42e-03 | 29 |
GO:004563721 | Lung | AAH | regulation of myeloid cell differentiation | 16/613 | 210/18723 | 1.55e-03 | 3.86e-02 | 16 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa041514 | Lung | IAC | PI3K-Akt signaling pathway | 60/1053 | 354/8465 | 7.03e-03 | 2.86e-02 | 1.90e-02 | 60 |
hsa0415111 | Lung | IAC | PI3K-Akt signaling pathway | 60/1053 | 354/8465 | 7.03e-03 | 2.86e-02 | 1.90e-02 | 60 |
hsa0415121 | Lung | AIS | PI3K-Akt signaling pathway | 57/961 | 354/8465 | 3.72e-03 | 2.00e-02 | 1.28e-02 | 57 |
hsa0415131 | Lung | AIS | PI3K-Akt signaling pathway | 57/961 | 354/8465 | 3.72e-03 | 2.00e-02 | 1.28e-02 | 57 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Breast | Healthy |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Cervix | ADJ |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Cervix | CC |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Cervix | Healthy |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Endometrium | EEC |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Esophagus | ESCC |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | HNSCC | ADJ |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | HNSCC | OSCC |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | HNSCC | Precancer |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Prostate | BPH |
CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Prostate | Healthy |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CSF3R | SNV | Missense_Mutation | c.241N>A | p.Gly81Arg | p.G81R | Q99062 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-33-4532-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CSF3R | SNV | Missense_Mutation | c.504N>T | p.Gln168His | p.Q168H | Q99062 | protein_coding | deleterious(0.01) | probably_damaging(0.915) | TCGA-33-4566-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
CSF3R | SNV | Missense_Mutation | c.164N>A | p.Leu55Gln | p.L55Q | Q99062 | protein_coding | deleterious(0.03) | probably_damaging(0.932) | TCGA-33-4566-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
CSF3R | SNV | Missense_Mutation | c.2351N>A | p.Gly784Asp | p.G784D | Q99062 | protein_coding | tolerated(0.1) | benign(0.158) | TCGA-34-5231-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CSF3R | SNV | Missense_Mutation | c.2308N>A | p.Gln770Lys | p.Q770K | Q99062 | protein_coding | tolerated(0.48) | benign(0.114) | TCGA-56-8307-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CSF3R | SNV | Missense_Mutation | novel | c.1726N>C | p.Ala576Pro | p.A576P | Q99062 | protein_coding | deleterious(0.01) | benign(0.394) | TCGA-68-7755-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unspecific | SD | |
CSF3R | SNV | Missense_Mutation | novel | c.1010N>C | p.Arg337Thr | p.R337T | Q99062 | protein_coding | deleterious(0.03) | possibly_damaging(0.899) | TCGA-6A-AB49-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CSF3R | SNV | Missense_Mutation | novel | c.38N>G | p.Ala13Gly | p.A13G | Q99062 | protein_coding | deleterious(0) | benign(0.366) | TCGA-NC-A5HL-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CSF3R | SNV | Missense_Mutation | c.1663N>C | p.Gly555Arg | p.G555R | Q99062 | protein_coding | tolerated(0.31) | benign(0.146) | TCGA-CN-4727-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD | |
CSF3R | SNV | Missense_Mutation | novel | c.1777G>T | p.Ala593Ser | p.A593S | Q99062 | protein_coding | tolerated(0.97) | benign(0.007) | TCGA-CN-6997-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | Filgrastim-SNDZ | FILGRASTIM | ||
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | FILGRAMSTIM | |||
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | PLX7486 | |||
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | agonist | CHEMBL1201568 | PEGFILGRASTIM | |
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | MAXY-G34 | |||
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | INS-19 | |||
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | agonist | 178101632 | FILGRASTIM | |
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | PLX-5622 | PLX-5622 | 22294205 | |
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | GLYCOPEG-GCSF | |||
1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | FILGRASTIM | FILGRASTIM |
Page: 1 2 3 4 |